Recent Insider Activity Suggests Potential Gains for Cassava Sciences Inc (SAVA)
Taking this into account, H.C. Wainwright upgraded its Cassava Sciences Inc [SAVA] rating to a Buy from a a Neutral
Taking this into account, H.C. Wainwright upgraded its Cassava Sciences Inc [SAVA] rating to a Buy from a a Neutral
Cassava Sciences, Inc. (SAVA) has seen a push of 7.26% in the aftermarket because the company announced that petition filed
U.S. stocks posted broad declines yesterday as investors grew cautious in the wake of Fed Chairman Jay Powell’s Wednesday comments
The biotech company Cassava Sciences updates that its Alzheimer’s drug, sumifilam, recorded positive results in treating Alzheimer’s patients in a
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.